

Draft LCD for Non-coronary Vascular Stents (DL30798)

Draft

Please note: This is a Draft policy.

Draft LCDs are works in progress that are available on the Medicare Coverage Database site for public review. Draft LCDs are not necessarily a reflection of the current policies or practices of the contractor.

Contractor Information

Draft Draft Draft

Contractor Name

Wisconsin Physicians Service Insurance Corporation

Contractor Number

00951, 00952, 00953, 00954, 05101, 05201, 05301, 05401, 05102, 05202, 05302, 05402, 52280

Contractor Type

Carrier - MAC - FI

LCD Information

Draft Draft Draft

LCD ID Number

DL30798

LCD Title

Non-coronary Vascular Stents

Contractor's Determination Number

CV-028

AMA CPT / ADA CDT Copyright Statement

CPT codes, descriptions and other data only are copyright 2009 American Medical Association (or such other date of publication of CPT). All Rights Reserved. Applicable FARS/DFARS Clauses Apply. Current Dental Terminology, (CDT) (including procedure codes, nomenclature, descriptors and other data contained therein) is copyright by the American Dental Association. © 2002, 2004 American Dental Association. All rights reserved. Applicable FARS/DFARS apply.

CMS National Coverage Policy

Title XVIII of the Social Security Act section 1862(a)(1)(A). This section excludes coverage and payment for items and services that are not considered reasonable and necessary for the diagnosis and treatment of illness or injury or to improve the function of a malformed body member.

Oversight Region

Region V

Projected Determination Effective Date

Original Determination Ending Date

Revision Effective Date

Revision Ending Date

Indications and Limitations of Coverage and/or Medical Necessity

Indications and Limitations of Coverage and/or Medical Necessity

LCD Description

Vascular stents are currently used to enhance primary patency following percutaneous transluminal angioplasty (PTA) in arteries and veins, usually at the site of stenotic or occlusive lesions. Stents may be used as an adjunct to technically inadequate PTA or in cases where PTA alone will not be expected to provide a durable result.

Vascular stents are typically made of woven, laser-cut or welded metal (stainless steel or nitinol) that permits the device to be compressed onto a catheter. The specific engineering of an individual stent will create a design that is balloon-expandable or self-expanding when deployed into a vessel with the use of radiological guidance. Stenting procedures may be deployed when a stenotic or occluded arterial or venous segment can be traversed with a catheter directed technique from a remote percutaneous site. Once deployed, the device remains permanently in the vessel.

Endovascular graft placement in the abdominal aorta is a treatment option to open procedures in the treatment of Abdominal Aortic Aneurysm (AAA).

Endovascular graft placement in the thoracic aorta is a treatment option to open procedures in the treatment of Thoracic Aortic Aneurysm (TAA).

Indications and Limitations of Coverage and/or Medical Necessity

I. Percutaneous Placement of Peripheral Grafts/Stents

Peripheral vascular stenting may be covered for patients with symptomatic arterial and venous disease resulting in an occlusive or aneurysmal process. Historically, these vascular lesions would be treated with direct surgical intervention. These surgical procedures may have significant co-morbidities (cardiac, pulmonary, renal and anesthetic associated complications) in the patient population affected with such arterial or venous diseases. Appropriate symptoms at the designated vascular sites include:

A. Renal artery:

Renal artery stenting is covered for:

1. Uncontrolled malignant hypertension despite multidrug therapy who have been found to have unilateral or bilateral renal artery stenosis equal to or greater than 50% by nuclear medicine studies, renal artery duplex, or renal arteriography (conventional catheter angiography, CT angiography, or MR angiography). Stenting meets coverage criteria for ostial lesions, for angioplasty with sub-optimal results, and for dissection. It is also met for patients with renal artery stenosis of < 50%, and suspected renovascular malignant hypertension. For patients with renal artery stenosis of < 50%, and suspected renovascular malignant hypertension, coverage criteria are met if renal vein renin studies indicate the hypertension is due to renal artery disease

2. Progressive renal insufficiency due to atherosclerotic stenosis of > 70%. Stenting meets coverage criteria for ostial lesions, for angioplasty with sub-optimal results, and for dissection. Data available to date suggests that in patients with abnormal renal function, treatment of hemodynamically significant unilateral or bilateral RAS is beneficial in improving and/or stabilizing renal function

3. Recurrent congestive heart failure, pulmonary edema, or coronary ischemia in the setting of stenosis of the renal artery(s) of > 60%. Stenting meets coverage criteria for ostial lesions, for angioplasty with suboptimal results, and for dissection. Cardiac syndromes attributable to RAS include exacerbations of congestive heart failure and coronary ischemia. Improving renal perfusion reduces renin production, which augments natriuresis and permits the use of angiotensin antagonists. Renal artery stenting in the setting of recurrent episodes of congestive heart failure and flash pulmonary edema has been shown to decrease the frequency of congestive heart failure, flash pulmonary edema, and the need for hospitalization in most patients.

4. Renal artery stenosis of > 50% in a transplanted kidney. Stenting meets coverage criteria for ostial lesions, for angioplasty with suboptimal results, and for dissection. PTA is the initial treatment of choice. Endovascular stent placement is used to treat suboptimal PTA result and to treat restenosis following PTA (reported restenosis occurs in 5%–30% of patients over a 6–8-month period).

5. There are no well-controlled prospective, randomized investigations to measure the relative risk and benefit of endovascular interventions (or associated medical therapies) in individuals with asymptomatic renal artery disease, and thus the role of such interventions remains controversial.

Recommendations regarding the role of percutaneous revascularization of asymptomatic renal disease are made largely on the basis of expert opinion and are not based on evidence that treatment of asymptomatic RAS improves any renal or systemic outcome, including renal preservation, blood pressure, or cardiovascular morbidity or mortality. Therefore, these recommendations are still considered controversial and must be individualized for the patient by each treating physician. The recommendations will likely be modified once controlled prospective data become available.

However, it appears that untreated RAS does result in excess mortality. We will cover renal atherosclerosis (ICD-9 code 440.1) when there is "hemodynamically significant stenosis of greater than 50% "

B. Mesenteric vessels.

This includes acute mesenteric ischemia, chronic mesenteric ischemia, mesenteric thrombosis, dissection or any other vascular insufficiency resulting in gastrointestinal symptoms; stenting of the mesenteric vessels is covered when angioplasty of the vessels would not suffice and after the patient has had a thorough medical evaluation and management of symptoms, and for whom surgical intervention is the likely alternative. In these situations, PTA and stent placement should be considered an alternative to surgery and not an addition to medical management. Recent studies have shown that the clinical efficacy and low complication rate of visceral arterial stenting compare well with the known morbidity and mortality of open surgical management of such occlusive mesenteric diseases. PTA with stent support as necessary is being used with increasing frequency for the revascularization of chronic and acute mesenteric ischemia. Based on significantly lower in-hospital mortality and lower complications, PTA/S appears to be reasonable firstline therapy in selected patients, particularly in the setting of chronic mesenteric ischemia. PTA/S may be useful in selected patients with acute mesenteric ischemia and appropriate anatomy.

C. Lower Extremity Arteries (iliac, femoral, popliteal):

Lifestyle limiting claudication, ischemic rest pain, nonhealing tissue ulceration, focal gangrene, dissection, impending failure of a lower extremity bypass graft.

The American Heart Association guidelines recommend endovascular therapy (including stent support, either as a primary intervention or in the setting of suboptimal angioplasty) for symptoms that interfere with job performance or lifestyle and who have had an inadequate response to exercise or pharmacologic therapy, as long as it is suggested that there is a reasonable likelihood of symptomatic improvement and the risk–benefit ratio is very high.

Stents can be useful in the iliac, femoral, popliteal, and tibial arteries as salvage therapy for suboptimal or failed result from angioplasty (e.g., persistent translesional gradient, residual diameter stenosis greater than 30%, or flow limiting dissection).

D. Hemodialysis Access graft/fistula: Stenosis, restenosis, and occlusion

A study by Vogel et al suggests that nitinol stents are safe and effective for treating dialysis access venous stenoses (central and peripheral) that are resistant to standard angioplasty.

E. Superior Vena Cava Superior vena cava syndrome and venous occlusions:

Superior vena cava syndrome, post radiation venous stenosis, and congenital stenosis, or webs, extrinsic venous compression and symptomatic post-traumatic venous stenoses.

A study by Nicholson et al suggests that percutaneous stenting in the setting of malignant superior vena cava syndrome meets the requirements of a palliative procedure significantly better than radiation therapy and that it should be the procedure of first choice.

F. Brachiocephalic Arteries: Subclavian steal syndrome, upper extremity claudication, ischemic rest pain of the arms and hand, non-healing tissue ulceration, focal gangrene, and dissection.

Subclavian arterial stent implantation is associated with better 1-year patency than PTA due to improved technical success. In a review by van Hattum et al, PTA with or without stent placement in a stenotic or occlusive brachiocephalic artery was found to be a safe procedure with a high initial success rate. Selective stent placement probably improves long-term success. PTA with selective stent placement should be considered the preferred treatment option.

G. Iliac veins and Inferior Vena Cava:

Venous stenting is becoming more frequent. The most common usage is the treatment of iliac vein compression in the setting of deep venous thrombosis or symptomatic venous stasis (ex. iliac vein compression syndrome, i.e. May Thurner). Jong-Youn Kim et al experienced decreased recurrent thrombosis in those patients treated with stenting as opposed to PTA alone. An article published in JVIR by Patel et al concludes that in the setting of May Thurner Syndrome, the involved left common iliac vein invariably requires stent placement. The published literature to date argues that stenting is the preferred treatment for iliac compression in the setting of DVT or symptomatic venous stasis.

H. Carotid Arteries

For national coverage requirements regarding carotid stents refer to the National Coverage Decision (NCD)

II. ANEURYSMS:

An aneurysm can develop anywhere along the aorta, about 75% occur in the abdominal section. The rest occur in the section that runs through the thorax. Thoracic aortic aneurysms, including those that extend from the descending thoracic aorta into the upper abdomen (thoracoabdominal aneurysms), account for about 25% of aortic aneurysms.

Aortic aneurysms are classified by shape, location along the aorta, and how they are formed.

The wall of the aorta is made up of three layers: a thin inner layer of smooth cells called the endothelium, a muscular middle layer which has elastic fibers in it called the media, and a tough outer layer called the adventitia. When the walls of the aneurysm have all three layers, they are called true aneurysms. If the wall of the aneurysm has only the outer layer remaining, it is called a pseudoaneurysm. Pseudoaneurysms may occur as a result of trauma when the inner layers are torn apart.

Most abdominal aortic aneurysms are caused by atherosclerosis. Thoracic aorta dissections are caused by an intimal tear. Hypertension is seen in at least 80% of these patients. Specific etiologies include degeneration of the thoracic media, Marfan's syndrome, coarctation of the aorta (as seen in Turner's syndrome, etc.), trauma, association with bicuspid aortic valves, but not directly related to atherosclerotic disease of the aorta.

Intervention is needed when aneurysmal changes of the aorta and or associated arteries (iliac, renal etc.) pose a risk of rupture. Intervention then can be through open surgery or by endovascular placement of a prosthesis.

A. Placement of Endovascular Prosthesis for Treatment of Abdominal Aortic Aneurysm (AAA)

1. Catheter delivery of an endovascular graft into the abdominal aorta and iliac arteries is a treatment alternative to open surgical replacement of the aneurysmal arteries. An endovascular device is composed of a fabric conduit supported with metallic components that are collapsed into a delivery system. It is introduced into the patient through surgical or percutaneous arterial access in the groin(s). Under angiographic guidance, the prosthesis is positioned to create a seal with a normal segment of arterial wall proximally and distally. When appropriately positioned, it is allowed to expand to full size and is anchored to the arterial wall with a variety of metal frameworks and/or attachment devices. The grafts may be composed of one or more modules that are positioned and docked to one another within the arterial system. Extensions of the graft and fastening hardware may be required to complete secure attachment of the devices to the arterial wall.

2. Very precise imaging of the patient's anatomy is required prior to delivery of an endovascular prosthesis as the device must be exactly the correct diameter and length to make a secure seal that will exclude the arterial blood flow from the aneurysm. Imaging is performed with digital computerized reconstruction arteriography, computerized tomography (radiographic and/or magnetic resonance) that allows multiple projections to fully appreciate the three dimensional configuration of the arterial tree. The arterial lumen may be imaged with intravascular ultrasound. Arterial embolization may be required to occlude side branches communicating with the aneurysm. Angioplasty may be used to enlarge the iliac arteries to permit delivery of the graft components.

3. Follow-up of an endovascular device is required to confirm that the device has not migrated and that the aneurysmal sac does not continue to enlarge. Follow-up studies also determine if there are endoleaks or other evidence of arterial flow in the excluded aneurysmal segment. The duration and intensity of follow-up will be determined when long-term series experiences with this technique are reported.

Recognized benefits of EVAR include reduced morbidity, ICU and hospital length of stay, and lower perioperative mortality, especially among elderly patients. This has led to the widespread adoption of this technology. In randomized prospective trials such as EVAR-1 trial and the DREAM trial were in-hospital mortality was 1.7% and 1.2% for EVAR and 6% and 4.6% for OSR, respectively.

In a recent analysis of 45,000 propensity score-matched Medicare beneficiaries treated by EVAR and OSR, mortality was significantly lower after EVAR (1.2% vs 4.8%; $P = .001$), with reduction in mortality most pronounced for those of advanced age (80 to 84 years).

B. Placement of Endovascular Prosthesis for Treatment of Thoracic Aortic Aneurysm (TAA)

Aneurysms of the thoracic aorta can be effectively treated by endovascular stent-grafting, but this approach requires suitable lengths of normal aorta proximal and distal to the defect for device fixation. If a major arterial branch lies within the aneurysm, the repair is more complex and may involve concomitant surgical or endoluminal procedures to reroute blood flow to vital organs or prevent continued perfusion of the aneurysm sac.

Because thoracic aneurysms often involve the abdominal aorta to some extent, the applicability and complexity of endograft repair depends on the number of critical vessels arising from or immediately adjacent to the aneurysm.

Before the operation, the patient will be assessed for feasibility of endovascular repair. This will include assessment of the general medical condition and other coexisting diseases, the surgical and anesthetic risk of the operation and whether the vascular configuration is suitable for stent graft. For non-emergency cases, a detailed CT scan and angiogram of the thoracic aorta and its branches will usually be performed; the size of the iliac arteries in the pelvis and the femoral arteries in the groin regions will be measured. Other imaging methods like MRI and ultrasound may be used. For emergency cases, a CT scan may be the only pre-operative investigation performed; angiogram will only be performed just before the procedure.

Endovascular stent grafts may be considered medically necessary for the treatment of descending thoracic aortic aneurysms of 23-37mm of inner aortic diameter. Diameter specifications are based on the parameters identified for FDA approved use of the GORE TAG endoprosthesis.

Results are available from the first completed multicenter trial directed at gaining approval from the US Food and Drug Administration for the endovascular repair of descending thoracic aortic aneurysms. In this multicenter study, early outcomes utilizing endovascular stent grafts in the treatment of descending aortic aneurysms were very encouraging when compared with those of a well-matched surgical cohort.

Preliminary results utilizing TEVAR in the treatment for acute and chronic dissections reveal a reduced risk of paraplegia and lower mortality compared with open surgical treatment.

An endovascular approach for ruptured descending thoracic aorta reduces early morbidity, mortality, and duration of hospitalization, while providing equivalent late outcomes. These data support TEVAR emerging as the preferred therapy for patients presenting with descending aortic rupture.

III. Conditions of Coverage

Coverage for above indications for non-coronary vascular stents depends on the use of a FDA approved stent. Several different stents are currently used in the medical community. Each device has specific indications described by the FDA for approved market uses. Stent placement is covered by Medicare only when an FDA approved stent is:

- used for the FDA approved indications, or
- used for the above indications supported by peer-reviewed medical literature.

A. Vascular stents are deployed either following suboptimal or failed percutaneous transluminal angioplasty (PTA) or as a planned adjunct to PTA (so-called primary stenting). Medical documentation for both circumstances is necessary.

A sub-optimal or failed PTA is defined as a technically successful dilation judged by the physician to be suboptimal or failed due to the presence of unfavorable lesion morphology such as:

1. An inadequate angiographic and/or hemodynamic result as defined by a 30% or greater residual stenosis post PTA, lesion recoil, or intimal flaps.
2. Flow-limiting dissections post PTA.
3. A 5-mm Hg or greater mean trans-stenotic pressure gradient post PTA.
4. Acute occlusion of the vessel post PTA.

B. A stent may be placed as a planned adjunct to PTA rather than in reaction to a failed PTA (so-called primary deployments). Primary stenting is likely to be performed for the following conditions.

1. Lesions unfavorable for primary PTA include those with:
 - a. significant calcification,
 - b. eccentricity,
 - c. extrinsic compression,
 - d. propensity for significant recoil,
 - e. potential PTA-induced vessel damage, including malignant and benign extrinsic venous obstruction, renal/visceral artery ostial stenosis, hemodialysis access stenosis
2. Chronic or acute arterial occlusions where there is risk of distal embolization.

C. A non-coronary intravascular stent(s) that carries an Investigational Device Exemption (IDE) may be covered under Medicare. Medicare coverage of IDE devices is predicated, in part, upon their status with the FDA. Payment will cease in the event a manufacturer loses its (or violates relevant IDE requirements necessitating FDA's withdrawal of) IDE approval. The FDA issues a special identifier number that corresponds to each device or stent(s) granted an IDE.

Coding Information



Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

11x	Hospital-inpatient (including Part A)
12x	Hospital-inpatient or home health visits (Part B only)
13x	Hospital-outpatient (HHA-A also) (under OPSS 13X must be used for ASC claims submitted for OPSS payment -- eff. 7/00)
83x	Special facility or ASC surgery-ambulatory surgical center (Discontinued for Hospitals Subject to Outpatient PPS; hospitals must use 13X for ASC claims submitted for OPSS payment -- eff. 7/00)

Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory; unless specified in the policy services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

032X	Radiology diagnostic-general classification
034X	Nuclear medicine-general classification
035X	Computed tomographic (CT) scan-general classification
040X	Other imaging services-general classification
061X	Magnetic resonance technology (MRT)-general classification
096X	Professional fees-general classification

CPT/HCPCS Codes

33880	ENDOVASCULAR REPAIR OF DESCENDING THORACIC AORTA (EG, ANEURYSM, PSEUDOANEURYSM, DISSECTION, PENETRATING ULCER, INTRAMURAL HEMATOMA, OR TRAUMATIC DISRUPTION); INVOLVING COVERAGE OF LEFT SUBCLAVIAN ARTERY ORIGIN, INITIAL ENDOPROTHESIS PLUS DESCENDING THORACIC AORTIC EXTENSION(S), IF REQUIRED, TO LEVEL OF CELIAC ARTERY ORIGIN
33881	ENDOVASCULAR REPAIR OF DESCENDING THORACIC AORTA (EG, ANEURYSM, PSEUDOANEURYSM, DISSECTION, PENETRATING ULCER, INTRAMURAL HEMATOMA, OR TRAUMATIC DISRUPTION); NOT INVOLVING COVERAGE OF LEFT SUBCLAVIAN ARTERY ORIGIN, INITIAL ENDOPROTHESIS PLUS DESCENDING THORACIC AORTIC EXTENSION(S), IF REQUIRED, TO LEVEL OF CELIAC ARTERY ORIGIN

- 33883 PLACEMENT OF PROXIMAL EXTENSION PROSTHESIS FOR ENDOVASCULAR REPAIR OF DESCENDING THORACIC AORTA (EG, ANEURYSM, PSEUDOANEURYSM, DISSECTION, PENETRATING ULCER, INTRAMURAL HEMATOMA, OR TRAUMATIC DISRUPTION); INITIAL EXTENSION
- 33884 PLACEMENT OF PROXIMAL EXTENSION PROSTHESIS FOR ENDOVASCULAR REPAIR OF DESCENDING THORACIC AORTA (EG, ANEURYSM, PSEUDOANEURYSM, DISSECTION, PENETRATING ULCER, INTRAMURAL HEMATOMA, OR TRAUMATIC DISRUPTION); EACH ADDITIONAL PROXIMAL EXTENSION (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)
- 33886 PLACEMENT OF DISTAL EXTENSION PROSTHESIS(S) DELAYED AFTER ENDOVASCULAR REPAIR OF DESCENDING THORACIC AORTA
- 33889 OPEN SUBCLAVIAN TO CAROTID ARTERY TRANSPOSITION PERFORMED IN CONJUNCTION WITH ENDOVASCULAR REPAIR OF DESCENDING THORACIC AORTA, BY NECK INCISION, UNILATERAL
- 33891 BYPASS GRAFT, WITH OTHER THAN VEIN, TRANSCERVICAL RETROPHARYNGEAL CAROTID-CAROTID, PERFORMED IN CONJUNCTION WITH ENDOVASCULAR REPAIR OF DESCENDING THORACIC AORTA, BY NECK INCISION
- 34800 ENDOVASCULAR REPAIR OF INFRARENAL ABDOMINAL AORTIC ANEURYSM OR DISSECTION; USING AORTO-AORTIC TUBE PROSTHESIS
- 34802 ENDOVASCULAR REPAIR OF INFRARENAL ABDOMINAL AORTIC ANEURYSM OR DISSECTION; USING MODULAR BIFURCATED PROSTHESIS (1 DOCKING LIMB)
- 34803 ENDOVASCULAR REPAIR OF INFRARENAL ABDOMINAL AORTIC ANEURYSM OR DISSECTION; USING MODULAR BIFURCATED PROSTHESIS (2 DOCKING LIMBS)
- 34804 ENDOVASCULAR REPAIR OF INFRARENAL ABDOMINAL AORTIC ANEURYSM OR DISSECTION; USING UNIBODY BIFURCATED PROSTHESIS
- 34805 ENDOVASCULAR REPAIR OF INFRARENAL ABDOMINAL AORTIC ANEURYSM OR DISSECTION; USING AORTO-UNIILIAC OR AORTO-UNIFEMORAL PROSTHESIS

34808 ENDOVASCULAR PLACEMENT OF ILIAC ARTERY OCCLUSION DEVICE (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)

34812 OPEN FEMORAL ARTERY EXPOSURE FOR DELIVERY OF ENDOVASCULAR PROSTHESIS, BY GROIN INCISION, UNILATERAL

34813 PLACEMENT OF FEMORAL-FEMORAL PROSTHETIC GRAFT DURING ENDOVASCULAR AORTIC ANEURYSM REPAIR (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)

34820 OPEN ILIAC ARTERY EXPOSURE FOR DELIVERY OF ENDOVASCULAR PROSTHESIS OR ILIAC OCCLUSION DURING ENDOVASCULAR THERAPY, BY ABDOMINAL OR RETROPERITONEAL INCISION, UNILATERAL

34825 PLACEMENT OF PROXIMAL OR DISTAL EXTENSION PROSTHESIS FOR ENDOVASCULAR REPAIR OF INFRARENAL ABDOMINAL AORTIC OR ILIAC ANEURYSM, FALSE ANEURYSM, OR DISSECTION; INITIAL VESSEL

34826 PLACEMENT OF PROXIMAL OR DISTAL EXTENSION PROSTHESIS FOR ENDOVASCULAR REPAIR OF INFRARENAL ABDOMINAL AORTIC OR ILIAC ANEURYSM, FALSE ANEURYSM, OR DISSECTION; EACH ADDITIONAL VESSEL (LIST SEPARATELY IN ADDITION TO CODE FOR PRIMARY PROCEDURE)

34830 OPEN REPAIR OF INFRARENAL AORTIC ANEURYSM OR DISSECTION, PLUS REPAIR OF ASSOCIATED ARTERIAL TRAUMA, FOLLOWING UNSUCCESSFUL ENDOVASCULAR REPAIR; TUBE PROSTHESIS

34831 OPEN REPAIR OF INFRARENAL AORTIC ANEURYSM OR DISSECTION, PLUS REPAIR OF ASSOCIATED ARTERIAL TRAUMA, FOLLOWING UNSUCCESSFUL ENDOVASCULAR REPAIR; AORTO-BI-ILIAC PROSTHESIS

34832 OPEN REPAIR OF INFRARENAL AORTIC ANEURYSM OR DISSECTION, PLUS REPAIR OF ASSOCIATED ARTERIAL TRAUMA, FOLLOWING UNSUCCESSFUL ENDOVASCULAR REPAIR; AORTO-BIFEMORAL PROSTHESIS

34833 OPEN ILIAC ARTERY EXPOSURE WITH CREATION OF CONDUIT FOR DELIVERY OF AORTIC OR ILIAC ENDOVASCULAR PROSTHESIS, BY ABDOMINAL OR RETROPERITONEAL INCISION, UNILATERAL

34834

OPEN BRACHIAL ARTERY EXPOSURE TO ASSIST
IN THE DEPLOYMENT OF AORTIC OR ILIAC
ENDOVASCULAR PROSTHESIS BY ARM
INCISION, UNILATERAL

34900

ENDOVASCULAR GRAFT PLACEMENT FOR
REPAIR OF ILIAC ARTERY (EG, ANEURYSM,
PSEUDOANEURYSM, ARTERIOVENOUS
MALFORMATION, TRAUMA)

37205

TRANSCATHETER PLACEMENT OF AN
INTRAVASCULAR STENT(S) (EXCEPT
CORONARY, CAROTID, AND VERTEBRAL
VESSEL), PERCUTANEOUS; INITIAL VESSEL

37206

TRANSCATHETER PLACEMENT OF AN
INTRAVASCULAR STENT(S) (EXCEPT
CORONARY, CAROTID, AND VERTEBRAL
VESSEL), PERCUTANEOUS; EACH ADDITIONAL
VESSEL (LIST SEPARATELY IN ADDITION TO
CODE FOR PRIMARY PROCEDURE)

37207

TRANSCATHETER PLACEMENT OF AN
INTRAVASCULAR STENT(S) (NON-CORONARY
VESSEL), OPEN; INITIAL VESSEL

37208

TRANSCATHETER PLACEMENT OF AN
INTRAVASCULAR STENT(S) (NON-CORONARY
VESSEL), OPEN; EACH ADDITIONAL VESSEL
(LIST SEPARATELY IN ADDITION TO CODE FOR
PRIMARY PROCEDURE)

37799

UNLISTED PROCEDURE, VASCULAR SURGERY

75952

ENDOVASCULAR REPAIR OF INFRARENAL
ABDOMINAL AORTIC ANEURYSM OR
DISSECTION, RADIOLOGICAL SUPERVISION AND
INTERPRETATION

75953

PLACEMENT OF PROXIMAL OR DISTAL
EXTENSION PROSTHESIS FOR ENDOVASCULAR
REPAIR OF INFRARENAL AORTIC OR ILIAC
ARTERY ANEURYSM, PSEUDOANEURYSM, OR
DISSECTION, RADIOLOGICAL SUPERVISION AND
INTERPRETATION

75954

ENDOVASCULAR REPAIR OF ILIAC ARTERY
ANEURYSM, PSEUDOANEURYSM,
ARTERIOVENOUS MALFORMATION, OR
TRAUMA, RADIOLOGICAL SUPERVISION AND
INTERPRETATION

75956

ENDOVASCULAR REPAIR OF DESCENDING THORACIC AORTA (EG, ANEURYSM, PSEUDOANEURYSM, DISSECTION, PENETRATING ULCER, INTRAMURAL HEMATOMA, OR TRAUMATIC DISRUPTION); INVOLVING COVERAGE OF LEFT SUBCLAVIAN ARTERY ORIGIN, INITIAL ENDOPROSTHESIS PLUS DESCENDING THORACIC AORTIC EXTENSION(S), IF REQUIRED, TO LEVEL OF CELIAC ARTERY ORIGIN, RADIOLOGICAL SUPERVISION AND INTERPRETATION

75957

ENDOVASCULAR REPAIR OF DESCENDING THORACIC AORTA (EG, ANEURYSM, PSEUDOANEURYSM, DISSECTION, PENETRATING ULCER, INTRAMURAL HEMATOMA, OR TRAUMATIC DISRUPTION); NOT INVOLVING COVERAGE OF LEFT SUBCLAVIAN ARTERY ORIGIN, INITIAL ENDOPROSTHESIS PLUS DESCENDING THORACIC AORTIC EXTENSION(S), IF REQUIRED, TO LEVEL OF CELIAC ARTERY ORIGIN, RADIOLOGICAL SUPERVISION AND INTERPRETATION

75958

PLACEMENT OF PROXIMAL EXTENSION PROSTHESIS FOR ENDOVASCULAR REPAIR OF DESCENDING THORACIC AORTA (EG, ANEURYSM, PSEUDOANEURYSM, DISSECTION, PENETRATING ULCER, INTRAMURAL HEMATOMA, OR TRAUMATIC DISRUPTION), RADIOLOGICAL SUPERVISION AND INTERPRETATION

75959

PLACEMENT OF DISTAL EXTENSION PROSTHESIS(S) (DELAYED) AFTER ENDOVASCULAR REPAIR OF DESCENDING THORACIC AORTA, AS NEEDED, TO LEVEL OF CELIAC ORIGIN, RADIOLOGICAL SUPERVISION AND INTERPRETATION

ICD-9 Codes that Support Medical Necessity

Renal (34833, 34834, 37205-37208, 75960)

403.00 - 403.91

HYPERTENSIVE CHRONIC KIDNEY DISEASE, MALIGNANT, WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED - HYPERTENSIVE CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE

404.00 - 404.93

HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, MALIGNANT, WITHOUT HEART FAILURE AND WITH CHRONIC KIDNEY DISEASE STAGE I THROUGH STAGE IV, OR UNSPECIFIED - HYPERTENSIVE HEART AND CHRONIC KIDNEY DISEASE, UNSPECIFIED, WITH HEART FAILURE AND CHRONIC KIDNEY DISEASE STAGE V OR END STAGE RENAL DISEASE

- 405.01 MALIGNANT RENOVASCULAR HYPERTENSION
- 405.11 BENIGN RENOVASCULAR HYPERTENSION
- 405.91 UNSPECIFIED RENOVASCULAR HYPERTENSION
- 440.1 ATHEROSCLEROSIS OF RENAL ARTERY
- 442.1 ANEURYSM OF RENAL ARTERY
- 443.23 DISSECTION OF RENAL ARTERY
- 447.1 STRICTURE OF ARTERY
- 447.3 HYPERPLASIA OF RENAL ARTERY
- 453.3 EMBOLISM AND THROMBOSIS OF RENAL VEIN
- 557.0 ACUTE VASCULAR INSUFFICIENCY OF INTESTINE
- 557.1 CHRONIC VASCULAR INSUFFICIENCY OF INTESTINE
- 557.9 UNSPECIFIED VASCULAR INSUFFICIENCY OF INTESTINE
- 584.5 - 584.9 ACUTE KIDNEY FAILURE WITH LESION OF TUBULAR NECROSIS - ACUTE KIDNEY FAILURE, UNSPECIFIED
- 585.6 END STAGE RENAL DISEASE
- 588.1 - 588.9 NEPHROGENIC DIABETES INSIPIDUS - UNSPECIFIED DISORDER RESULTING FROM IMPAIRED RENAL FUNCTION
- 593.81 VASCULAR DISORDERS OF KIDNEY
- 747.62 RENAL VESSEL ANOMALY
- 996.81 COMPLICATIONS OF TRANSPLANTED KIDNEY

Lower Extremity Arteries (except tibial), (34833, 34834, 34900, 37205-37208, 75960)

- 249.70 SECONDARY DIABETES MELLITUS WITH PERIPHERAL CIRCULATORY DISORDERS, NOT STATED AS UNCONTROLLED, OR UNSPECIFIED
- 249.71 SECONDARY DIABETES MELLITUS WITH PERIPHERAL CIRCULATORY DISORDERS, UNCONTROLLED

250.70 - 250.73	DIABETES WITH PERIPHERAL CIRCULATORY DISORDERS, TYPE II OR UNSPECIFIED TYPE, NOT STATED AS UNCONTROLLED - DIABETES WITH PERIPHERAL CIRCULATORY DISORDERS, TYPE I [JUVENILE TYPE], UNCONTROLLED
440.0	ATHEROSCLEROSIS OF AORTA
440.21	ATHEROSCLEROSIS OF NATIVE ARTERIES OF THE EXTREMITIES WITH INTERMITTENT CLAUDICATION
440.22	ATHEROSCLEROSIS OF NATIVE ARTERIES OF THE EXTREMITIES WITH REST PAIN
440.23	ATHEROSCLEROSIS OF NATIVE ARTERIES OF THE EXTREMITIES WITH ULCERATION
440.24	ATHEROSCLEROSIS OF NATIVE ARTERIES OF THE EXTREMITIES WITH GANGRENE
440.29	OTHER ATHEROSCLEROSIS OF NATIVE ARTERIES OF THE EXTREMITIES
441.02	DISSECTION OF AORTA ABDOMINAL
442.2	ANEURYSM OF ILIAC ARTERY
442.3	ANEURYSM OF ARTERY OF LOWER EXTREMITY
443.22	DISSECTION OF ILIAC ARTERY
443.23	DISSECTION OF RENAL ARTERY
443.29	DISSECTION OF OTHER ARTERY
443.9	PERIPHERAL VASCULAR DISEASE UNSPECIFIED
444.21	ARTERIAL EMBOLISM AND THROMBOSIS OF UPPER EXTREMITY
444.22	ARTERIAL EMBOLISM AND THROMBOSIS OF LOWER EXTREMITY
444.81	EMBOLISM AND THROMBOSIS OF ILIAC ARTERY
444.89	EMBOLISM AND THROMBOSIS OF OTHER ARTERY
447.1	STRICTURE OF ARTERY
447.8	OTHER SPECIFIED DISORDERS OF ARTERIES AND ARTERIOLES
707.10 - 707.19	UNSPECIFIED ULCER OF LOWER LIMB - ULCER OF OTHER PART OF LOWER LIMB
729.5	PAIN IN LIMB
747.22	CONGENITAL ATRESIA AND STENOSIS OF AORTA

785.4	GANGRENE
Hemodialysis Access Graft/Fistula (37205-37208, 75960)	
440.31	ATHEROSCLEROSIS OF AUTOLOGOUS VEIN BYPASS GRAFT OF THE EXTREMITIES
440.32	ATHEROSCLEROSIS OF NONAUTOLOGOUS BIOLOGICAL BYPASS GRAFT OF THE EXTREMITIES
585.6	END STAGE RENAL DISEASE
996.1	MECHANICAL COMPLICATION OF OTHER VASCULAR DEVICE IMPLANT AND GRAFT
996.73	OTHER COMPLICATIONS DUE TO RENAL DIALYSIS DEVICE IMPLANT AND GRAFT
996.74	OTHER COMPLICATIONS DUE TO OTHER VASCULAR DEVICE IMPLANT AND GRAFT
Superior Vena Cava (37205-37208, 75960)	
459.2	COMPRESSION OF VEIN
747.49	OTHER ANOMALIES OF GREAT VEINS
784.2	SWELLING MASS OR LUMP IN HEAD AND NECK
990	EFFECTS OF RADIATION UNSPECIFIED
Brachiocephalic Arteries (including subclavian, except carotid, vertebral and cerebral) (37205-37208, 75960)	
435.2	SUBCLAVIAN STEAL SYNDROME
440.21	ATHEROSCLEROSIS OF NATIVE ARTERIES OF THE EXTREMITIES WITH INTERMITTENT CLAUDICATION
440.22	ATHEROSCLEROSIS OF NATIVE ARTERIES OF THE EXTREMITIES WITH REST PAIN
440.23	ATHEROSCLEROSIS OF NATIVE ARTERIES OF THE EXTREMITIES WITH ULCERATION
440.24	ATHEROSCLEROSIS OF NATIVE ARTERIES OF THE EXTREMITIES WITH GANGRENE
444.21	ARTERIAL EMBOLISM AND THROMBOSIS OF UPPER EXTREMITY
Abdominal Aorta (34800, 34802, 34803, 34804, 34805, 34808, 34813, 34820, 34825, 34826, 34830, 34831, 34832, 34833, 34834, 37205-37208, 75952, 75953, 75954, 75960)	
441.02	DISSECTION OF AORTA ABDOMINAL
441.3	ABDOMINAL ANEURYSM RUPTURED
441.4	ABDOMINAL ANEURYSM WITHOUT RUPTURE
442.1	ANEURYSM OF RENAL ARTERY
442.2	ANEURYSM OF ILIAC ARTERY
902.0	INJURY TO ABDOMINAL AORTA

Thoracic Aorta: 33880, 33881, 33883, 33884, 33886, 33889, 33891, 34820, 34833, 34834	
441.01	DISSECTION OF AORTA THORACIC
441.03	DISSECTION OF AORTA THORACOABDOMINAL
441.1	THORACIC ANEURYSM RUPTURED
441.2	THORACIC ANEURYSM WITHOUT RUPTURE
441.6	THORACOABDOMINAL ANEURYSM RUPTURED
441.7	THORACOABDOMINAL ANEURYSM WITHOUT RUPTURE
901.0	INJURY TO THORACIC AORTA

Diagnoses that Support Medical Necessity

ICD-9 Codes that DO NOT Support Medical Necessity

ICD-9 Codes that DO NOT Support Medical Necessity Asterisk Explanation

Diagnoses that DO NOT Support Medical Necessity

General Information



Documentation Requirements

1. Documentation supporting the medical necessity of this item, such as ICD-9 codes, must be submitted with each claim. Claims submitted without such evidence will be denied as being not medically necessary.
2. Documentation may be required with claims for Endovascular Repair of AAA or TAA. See Coding Guidelines.

Appendices

Utilization Guidelines

*- An asterisk indicates a revision to that section of the policy.

This policy does not reflect the sole opinion of the contractor or Contractor Medical Director. Although the final decision rests with the MAC contractor this policy was developed in cooperation with advisory groups which include representatives from various specialties, and adapted for the purpose of converting to MAC jurisdiction.

Sources of Information and Basis for Decision

I. Society of Cardiovascular & Interventional Radiology (SCVIR), Government Affairs Committee; Society for Vascular Surgery (SVS); International Society for Cardiovascular Surgery-North American Chapter (ISCVS-NA)

*ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic); J. Am. Coll. Cardiol. 2006; 47; 1-192

II. Bibliography

Selected Literature References to Renal Artery Stenting

WHITE CJ, RAMEE SR, COLINS TJ, ESCOBAR A, JENKINS JS, SHAW D. "Renal artery stent placement: utility in lesions difficult to treat with balloon angioplasty.", J Am Coll Cardiol 1997 Nov 15;30(6):1445-50. Department of Cardiology, Ochsner Clinic, New Orleans, Louisiana 70121, USA.

MOSS JG, CONNELL JM, DOMINICZAK AF, MACLEOD MF, BAXTER GM, HARDEN PN, RODGER RS, JUNOR BJ, BRIGGS JD. "Effect of renal-artery stenting on progression of renovascular renal failure [see comments]", Lancet 1997 Apr 19;349 (9059):1133-6. Renal Unit, Western Infirmary, Glasgow, UK.

LANGER M, BLUM U, GABELMANN A, BUITRAGO-TELLEZ C, KRUMME B, FLUGEL P, LEHNERT T, SCHOLLMAYER P. "Treatment of ostial renal-artery stenoses with vascular endoprostheses after unsuccessful balloon angioplasty [see comments]", N Engl J Med 1997 Feb 13;336 (7):459-65. Department of Diagnostic Radiology, University Hospital Freiburg, Germany

RUNDBACK JH, JACOBS JM. "Percutaneous renal artery stent placement for hypertension and azotemia: pilot study", Am J Kidney Dis 1996 Aug;28 (2):214-9. Department of Radiology, Muhlenberg Hospital Center, Bethlehem, PA, USA.

DORROS G, DUFEK C, MATHIAK L, JAFF M, JAIN A. "Follow-up of primary Palmaz-Schatz stent placement for atherosclerotic renal artery stenosis.", Am J Cardiol 1995 May 15;75 (15):1051-5. William Dorros-Isadore Feuer Interventional Cardiovascular Disease Foundation, Ltd., Milwaukee, Wisconsin 53215-3660, USA.

REES CR, DAKE MD, SCHWARTEN DE, BECKER GJ, EHRMAN KO, NOELDE G, PALMAZ JC, RICHTER GM, KATZEN BT. "Palmaz stent in atherosclerotic stenoses involving the ostia of the renal arteries: preliminary report of a multicenter study.", Radiology 1991 Nov;181 (2):507-14. Department of Radiology, University of Texas Health Science Center, San Antonio.

*PAUL S. WATSON, MBBS; PETER HADJIPETROU, MBBS; STEPHEN V. COX, MBBS; THOMAS C. PIEMONTE, MD; ANDREW C. EISENHAUER, MD Effect of Renal Artery Stenting on Renal Function and Size in Patients with Atherosclerotic Renovascular Disease. Circulation. 2000;102:1671-1677

*C. J. COOPER AND T. P. MURPHY The Case for Renal Artery Stenting for Treatment of Renal Artery Stenosis *Circulation*, January 16, 2007; 115(2): 263 - 270.

*ZELLER T, FRANK U, MULLER C, BURGELIN K, SINN L, BESTEHORN HP, COOK-BRUNS N, NEUMANN F. Predictors of improved renal function after percutaneous stent-supported angioplasty of severe atherosclerotic ostial renal artery stenosis. *Circulation*. 2003; 108: 2244–2249.

*B. H GRAY, J. W OLIN, M. B. CHILDS, T. M SULLIVAN, AND J M. BACHARACH Clinical benefit of renal artery angioplasty with stenting for the control of recurrent and refractory congestive heart failure *Vascular Medicine*, November 1, 2002; 7(4): 275 - 279.

*BEECROFT JR, RAJAN DK, CLARK TW, ROBINETTE M, STAVROPOULOS SW. Transplant renal artery stenosis: outcome after percutaneous intervention. *J Vasc Interv Radiol* 2004;15:1407–1413.

*SIERRE SD, RAYNAUD AC, CARRERES T, SAPOVAL MR, BEYSSEN BM, GAUX JC. Treatment of recurrent transplant renal artery stenosis with metallic stents. *J Vasc Interv Radiol* 1998;9:639–644.

Selected Literature References to Mesenteric Artery Stenting

*MELHEM J. SHARAFUDDIN, MD,A,B CRAIG H. OLSON, BS,A SHILIANG SUN, MD,B TIMOTHY F. KRESOWIK, MD, FACS,A AND JOHN D. CORSON, MB, CHB, FRCS(ENG), FRCS(ED), FACS,. Endovascular treatment of celiac and mesenteric arteries stenoses: Applications and results. *JOURNAL OF VASCULAR SURGERY* Volume 38, Number 4

*MARC L. SCHERMERHORN, MD, KRISTINA A. GILES, MD, ALLEN D. HAMDAN, MD, MARK C. WYERS, MD, FRANK B. POMPOSELLI MD. Mesenteric Revascularization: management and outcomes in the United States, 1988-2006., *J Vasc Surg* 2009;50:341-8

Selected Literature References to Brachiocephalic Arteries Stenting

CRIADO FJ, QUERAL LA. “The role of angioplasty and stenting in the treatment of occlusive lesions of supra-aortic trunks.”, *J Mal Vasc* 1996;21 Suppl A:132-8. Division of Vascular Surgery, Maryland Vascular Institute, Union Memorial Hospital, Baltimore MD, USA.

LYON RD, SHONNARD KM, MCCARTER DL, HAMMOND SL, FERGUSON D, RHOLL KS. “Supra-aortic arterial stenoses: management with Palmaz balloon-expandable intraluminal stents.”, *J Vasc Interv Radiol* 1996 Nov-Dec;7 (6):825-35. Department of Radiology, Fitzsimmons Army Medical Center, Aurora, CO 80045-5001, USA

DORROS G, BATES MC, KUMAR K, PALMER L, DUFEK C, MATHIAK L. “Primary stent deployment in occlusive subclavian artery disease.”, *Cathet Cardiovasc Diagn* 1995 Apr;34 (4):281-5. William Dorros-Isadore Feuer Interventional Cardiovascular Disease Foundation, Ltd., Milwaukee, WI 53215, USA.

MATHIAS KD, LUTH I, HAARMANN P. “Percutaneous transluminal angioplasty of proximal subclavian artery occlusions.”, *Cardiovasc Intervent Radiol* 1993 Jul-Aug;16 (4):214-8. Department of Diagnostic Radiology, Stadtische Kliniken, Federal Republic of Germany.

VOWERK D, SCHURMANN K, GUENTHER RW. “Stent Placement on fresh venous thrombosis.”, *Cardiovasc Intervent Radiol* 1997 Sep-Oct; 20(5):359-63. Department of Diagnostic Radiology, Technical University of Aachen, Fauweistrasee, D-52057 Aachen Germany.

MOTARJEME A. “Percutaneous transluminal angioplasty of supra-aortic vessels.”, *J Endovasc Surg* 1996 May;3 (2):171-81. Midwest Vascular Institute, Good Samaritan Hospital, Downers Grove, Illinois, USA.

*ELINE S. VAN HATTUM, JEAN-PAUL P.M. DE VRIES, FERRY LALEZARI, JOS C. VAN DEN BERG, FRANS L. Moll Angioplasty with or without Stent Placement in the Brachiocephalic Artery: Feasible and Durable? A Retrospective Cohort Study *Journal of Vascular and Interventional Radiology* September 2007 (Vol. 18, Issue 9, Pages 1088-1093)

Selected Literature References to Aortoiliac and Peripheral Arteries Stenting

STRECKER EP, BOOS IB, GOTTMANN D. "Femoropopliteal artery stent placement: evaluation of long-term success.", *Radiology* 1997 Nov;205 (2):375-83. Department of Radiology, Diakonissen Hospital, Karlsruhe, Germany.

BOSCH JL, HUNINK MG. "Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease [published erratum appears in *Radiology* 1997 Nov;205

(2):584]", *Radiology* 1997 Jul;204(1):87-96. Department of Health Sciences, University of Groningen, The Netherlands.

SULLIVAN TM, CHILDS MB, BACHARACH JM, GRAY BH, PIEDMONTE MR. "Percutaneous transluminal angioplasty and primary stenting of the iliac arteries in 288 patients.", *J Vasc Surg* 1997 May;25 (5):829-38;discussion 838-9. Department of Vascular Surgery, Cleveland Clinic Foundation, OH 44195, USA.

NICHOLSON AA, GAINES PA, DYET JF, COOK AM, CLEVELAND T, WILKINSON AR, GALLOWAY JM, BEARD J. "Treatment of chronic iliac artery occlusions by means of percutaneous endovascular stent placement.", *J Vasc Interv Radiol* 1997 May-Jun;8 (3):349-53. Department of Radiology, Hull Royal Infirmary, England.

MAYNAR M, REYES R, FERRAL H, GORRIZ E, LOPERA J, CARREIRA J, CASTANEDA WR. "Treatment of chronic iliac artery occlusions with guide wire recanalization and primary stent placement.", *J Vasc Interv Radiol* 1997 Nov-Dec;8 (6):1049-55. Department of Radiology, Hospital Ntra Sra del Pino, Las Palmas de Gran Canaria, Spain.

DORFMAN GS, MURPHY TP, CARNEY WI JR, WEBB MS, LAMBIASE RE, HAAS RA, MORIN CJ. "Percutaneous revascularization of complex iliac artery stenoses and occlusions with use of Wallstents: three-year experience.", *J Vasc Interv Radiol* 1996 Jan-Feb;7 (1):21-7. Division of Vascular and Interventional Radiology, Rhode Island Hospital, Brown University School of Medicine, Providence 02903.

BALLARD JL, TAYLOR FC, SPARKS SR, KILLEEN JD. "Stenting without thrombolysis for aortoiliac occlusive disease; experience in 14 high-risk patients.", *Ann Vasc Surg* 1995 Sep;9 (5):453-8. Division of Vascular Surgery, Loma Linda University Medical Center, CA 92354, USA.

PALMAZ JC, MURPHY KD, ENCARNACION CE, LE VA. "Iliac artery stent placement with the Palmaz stent: follow-up study.", *J Vasc Interv Radiol* 1995 May-Jun;6 (3):321-9. Department of Radiology, University of Texas Health Science Center, San Antonio 78284-7800 USA.

BECKER GJ. "Intravascular stents. General principles and status of lower-extremity arterial applications.", *Circulation* 1991 Feb;83(2 Suppl):I122-36. Miami Vascular Institute, Baptist Hospital of Miami, FL 33176.

*SCHILLINGER M, SABETI S, LOEWE C, DICK P, AMIGHI J, MLEKUSCH W, SCHLAGER O, CEJNA M, LAMMER J, MINAR E. Balloon Angioplasty versus Implantation of Nitinol Stents in the Superficial Femoral Artery., *N Engl J Med* 354:1879, May 4, 2006

*HIRSCH AT, HASKAL ZJ, HERTZER NR, ET AL. ACC/AHA 2005 GUIDELINES FOR THE MANAGEMENT OF PATIENTS WITH PERIPHERAL ARTERIAL DISEASE (LOWER EXTREMITY, RENAL, MESENTERIC, AND ABDOMINAL AORTIC): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients with Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *J Am Coll Cardiol* 2006; 47:1239-312.

*DONALD PONEC, MICHAEL R. JAFF, JAMES SWISCHUK, ANDY FEIRING, JOHN LAIRD, MUNISH MEHRA, JEFFREY J. POPMA, DENNIS DONOHOE, BRIAN FIRTH, EMILY KEIM, DAVID SNEAD, CRISP Study Investigators The Nitinol SMART Stent vs Wallstent for Suboptimal Iliac Artery Angioplasty: CRISP-US Trial Results *Journal of Vascular and Interventional Radiology* September 2004 (Vol. 15, Issue 9, Pages 911-918)

*JONATHAN D. BEARD, CHM, MED, FRCS, Which is the best revascularization for critical limb ischemia: Endovascular or open surgery? *J Vasc Surg* 2008; 48: 11S-16S.)

*KAREN MCQUADE, DENNIS GABLE, STEPHEN HOHMAN, GREG PEARL, BRIAN THEUNE Randomized comparison of ePTFE/nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass in the treatment of superficial femoral artery occlusive disease. *Journal of Vascular Surgery* January 2009 (Vol. 49, Issue 1, Pages 109-116.e9)

*MARTIN SCHILLINGER, MD; MARKUS HAUMER, MD; SABINE SCHILLINGER, MD; RAMAZANALI AHMADI, MD; AND ERICH MINAR, MD Risk Stratification for Subclavian Artery Angioplasty: Is There an Increased Rate of Restenosis After Stent Implantation? *Journal of Endovascular Therapy*: Vol. 8, No. 6, pp. 550–557.

Selected Literature References to Venous Stenting

CHACON LOPEZ-MUNIZ JI, GARCIA GARCIA L, LANCIEGO PEREZ C, et al. “Treatment of superior and inferior vena cava syndromes of malignant cause with Wallstent catheter placed percutaneously.” *Am Clin oncol* 1997;20 (3):393-297.

DONDELINGER RF, GOFFETTE P, KURDZIEL J, et al. “Expandable metal stents for stenoses of the venae cavae and large veins.” *Sem in Intervent Radiol* 1991;8 (4):252-263.

DYET JF, NICHOLSON AA, COOK AM. “The use of the Wallstent endovascular prosthesis in the treatment of malignant obstruction of the superior vena cava.” *Clin Radiology* 1993;48:381-385.

FURUI S, SAWADA S, KURAMOTO K, et al. “Gianturco stent placement in malignant cava obstruction: analysis of factors for predicting the outcome.” *Radiology* 1995;195:147-152.

KEE ST, KINOSHITA L, RAZAVI MK, et al. “Superior vena cava syndrome treatment with catheter-directed thrombolysis and endovascular stent placement.” *Radiology* 1998;206:187-193.

NICHOLSON A, ETTLES D, ARNOLD A, et al. “Treatment of malignant superior vena cava obstruction: metal stents or radiation therapy.” *JVIR* 1997;8:781-788.

FUNAKI B, CHANG TC, ZALESKI GX, LIN BH, LEEF J. “Treatment of inferior vena cava obstruction in hemodialysis patients using Wallstents: early and intermediate results.” *AJR Am J Roentgenol* 1998 Jul;171 (1):125-8. Department of Radiology, The University of Chicago Hospitals, IL 60637, USA.

WILLIAMS DM, PFAMMATTER T, LANE KL, CAMPBELL DA JR, CHO KJ. "Suprahepatic caval anastomotic stenosis complicating orthotopic liver transplantation: treatment with percutaneous transluminal angioplasty, Wallstent placement, or both.", *AJR Am J Roentgenol* 1997 Feb;168 (2):477-80. Department of Radiology, University of Michigan Hospitals, Ann Arbor 48109, USA.

FONTAINE AB, NIJIAR A. "Treatment of iatrogenic superior vena cava syndrome with a vascular stent.", *J Vasc Interv Radiol* 1996 Jul-Aug;7 (4):607-9. Department of Radiology, Ohio State University Medical Center, Columbus 43210, USA.

CAMUNEZ F, SIMO G, BANARES R, ECHENAGUSIA A, QUEVEDO P, CALLEJA IJ, FERREIROA JP. "Stenosis of the inferior vena cava after liver transplantation: treatment with Gianturco expandable metallic stents.", *Cardiovasc Intervent Radiol* 1995 Jul-Aug;18 (4):212-6. Department of Radiology, Hospital General Universitario Gregorio Maranon, Madrid, Spain.

JAQUES PF, MAURO MA, CRIADO E, MARSTON WA, KEAGY BA. "Proximal venous outflow obstruction in patients with upper extremity arteriovenous dialysis access.", *Ann Vasc Surg* 1994 Nov;8 (6):530-5. Division of Vascular Surgery, University of North Carolina at Chapel Hill School of Medicine.

O'LAUGHLIN MP, DODDS GA 3RD, HARRISON JK, WILSON JS, KISSLO KB, BASHORE TM. "Relief of superior vena cava syndrome due to fibrosing mediastinitis using the Palmaz stent.", *Chest* 1994 Jul;106 (1):315-8. Department of Medicine, Duke University Medical Center, Durham, NC 27710.

TREROTOLA SO, MAGEE CA, LUND GB, NEWMAN JS, OLSON JL, ANDERSON JH, OSTERMAN FA JR, SAMPHILIPO MA. "Palmaz stent in the treatment of central venous stenosis: safety and efficacy of redilation.", *Radiology* 1994 Feb;190 (2):379-85. Department of Interventional Radiology, Russell H. Morgan Department of Radiology and Radiological Science, John Hopkins Medical Institutions, Baltimore, MD.

ROSCH J, UCHIDA BT, TREROTOLA SO, VENBRUX AC, MITCHELL SE, SAVANDER SJ, LUND GB, NEWMAN JS, KLEIN AS, MITCHELL MC. "Long-term results with the use of metallic stents in the inferior vena cava for treatment of Budd-Chiari syndrome.", *J Vasc Interv Radiol* 1994 May-Jun;5 (3):411-6. Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, MD 21287.

KISHI K, SONOMURA T, NISHIDA N, MITSUZANE K, KOBAYASHI H, YANG RJ, SATO M, YAMADA R, SHIRAI S. "Self-expandable metallic stent therapy for superior vena cava syndrome: clinical observations.", *Radiology* 1993 Nov;189 (2):531-5. Department of Radiology, Saiseikai Wakayama Hospital, Japan.

OUDKERK M, HEYSTRATEN FM, STOTER G. "Stenting in malignant vena caval obstruction.", *Cancer* 1993 Jan 1;71 (1):142-6. Department of Diagnostic Radiology, Rotterdam Cancer Institute, The Netherlands.

WRIGHT KC, WALLACE S, GIANTURCO C, CHARNSANGAVEJ C, CARRASCO CH. "Use of the Gianturco self-expanding stent in stenoses of the superior and inferior venae cavae.", *J Vasc Interv Radiol* 1992 May;3 (2):409-19. Division of Diagnostic Imaging, University of Texas M.D. Anderson Cancer Center, Houston 77030.

ROSCH J, IVANCEV K, UCHIDA BT, ANTONOVIC R, BARTON RE, KELLER FS, HALL LD, PETERSEN BD. "Gianturco-Rosch expandable Z-stents in the treatment of superior vena cava syndrome.", *Cardiovasc Intervent Radiol* 1992 Sep-Oct;15 (5):319-27. Charles Dotter Institute for Interventional Therapy, Oregon Health Sciences University, Portland 97201.

SCHILD H, IRVING JD, ADAM A, ZOLLIKOFER CL, MAYNAR M, DICK R, DONDELINGER RF, REIDY JF. "Gianturco self-expanding stents: clinical experience in the vena cava and large veins.", *Cardiovasc Intervent Radiol* 1992 Sep-Oct;15 (5):328-33. Department of Radiology, Centre Hospitalier, Luxembourg, England.

ELSON JD, BECKER GJ, WHOLEY MH, EHRMAN KO. "Vena caval and central venous stenoses: Management with Palmaz balloon-expandable intraluminal stents.", J Vasc Interv Radiol 1991 May;2 (2):215-23. Department of Radiology, Clarkson Hospital, Omaha, NE 68105.
Selected Literature References to Hemodialysis Access and Associated Vessels Stenting

FUNAKI B, CHANG TC, ZALESKI GX, LIN BH, LEEF J. "Treatment of inferior vena cava obstruction in hemodialysis patients using Wallstents: early and intermediate results.", AJR Am J Roentgenol 1998 Jul;171 (1):125-8. Department of Radiology, The University of Chicago Hospitals, IL 60637, USA.

HOVSEPIAN DM, VESELY TM, PILGRIM TK, COYNE DW, SHENOY S. "Upper extremity central venous obstruction in hemodialysis patients: treatment with Wallstents.", Radiology 1997 Aug;204 (2):343-8. Department of Diagnostic Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA.

PENGLOAN J, ABAZA M, BLANCHARD D, SAPOVAL M, TURMEL-RODRIGUES LA, BAUDIN S, TESTOU D, MOUTON A. "Wallstents and Craggstents in hemodialysis grafts and fistulas: results for selective indications.", J Vasc Interv Radiol 1997 Nov-Dec;8 (6):975-82. Department of Cardiovascular Radiology, Clinique St-Gatien, Tours, France.

RAMEE SR, MONEY SR, SHAW D, BHATIA DS, OCHSNER JL, CROCKETT DE, CHATMAN D, CHARAMSEY SA, MULINGTAPANG RF. "Comparison of surgical bypass and percutaneous balloon dilatation with primary stent placement in the treatment of central venous obstruction in the dialysis patient: one-year follow-up.", Ann Vasc Surg 1996 Sep;10 (5):452-5. Department of Surgery, Alton Ochsner Medical Foundation, New Orleans, LA, USA.

DOLMATCH GL, GRAY RJ, HORTON KM, RUNDBACK JH, ANAISE D, AQUINO AO, CURRIER CB, LIGHT JA, SASAKI TM. "Use of Wallstents for hemodialysis access-related venous stenoses and occlusions untreatable with balloon angioplasty.", Radiology 1995 May;195 (2):479-84. Department of Radiology, Washington Hospital Center, Washington, DC 20010, USA.

BOHNDORF K, VORWERK D, KISTLER D, MANN H, GUENTHER RW, KEULERS P, ALZEN G, SOHN M. "Venous stenosis and occlusion in hemodialysis shunts: follow-up results of stent placement in 65 patients.", Radiology 1995 Apr;195 (1):140-6. Department of Diagnostic Radiology, Technical University of Aachen, Germany.

JAQUES PF, MAURO MA, CRIADO E, MARSTON WA, KEAGY BA. "Proximal venous outflow obstruction in patients with upper extremity arteriovenous dialysis access.", Ann Vasc Surg 1994 Nov;8 (6):530-5. Division of Vascular Surgery, University of North Carolina at Chapel Hill School of Medicine.

SHOENFELD R, HERMANS H, NOVICK A, BRENER B, CORDERO P, EISENBUD D, MODY S, GOLDENKRANZ R, PARSONNET V. "Stenting of proximal venous obstructions to maintain hemodialysis access.", J Vasc Surg 1994 Mar;19 (3):532-9. Department of Radiology, Newark Beth Israel Medical Center, NJ 07112.

Abstract:

TURMEL-RODRIGUES L, PENGLOAN J, BLANCHIER D, ABAZA M, BIRMELE B, HAILLOT O, BLANCHARD D. "Insufficient dialysis shunts: improved long-term patency rates with close hemodynamic monitoring, repeated percutaneous balloon angioplasty, and stent placement.", Radiology 1993 Apr;187 (1):273-8. Department of Radiology, Clinique St Gatien, Tours, France.

SCHATZ R, MATTHEWS R, CLUGSTON R, EISENHAUER A, DAKE M, FEINSTEIN E. "Balloon expandable stents to treat central venous stenoses in hemodialysis patients.", Am J Nephrol 1992;12 (6):451-6. Cardiac Catheterization and Interventional Laboratory, Hospital of the Good Samaritan, Los Angeles, CA 90017.

ZOLLIKOFER CL, ANTONUCCI F, STUCKMANN G, MATTIAS P, SALOMONOWITZ EK, BRUHLMANN WF. "Use of the Wallstent in the venous system including hemodialysis-related stenoses.", *Cardiovasc Intervent Radiol* 1992 Sep-Oct;15 (5):334-41. Department of Radiology, Kantonsspital Winterthur, Switzerland.

ZOLLIKOFER CL, ANTONUCCI F, SALOMONOWITZ E, STUCKMANN G, STIEFEL M, HUGENTOBLER M. "Hemodialysis related venous stenoses: treatment with self-expanding endovascular prostheses.", *Eur J Radiol* 1992 May-Jun;14 (3):195-200. Department of Radiology, Kantonsspital Winterthur, Switzerland.

HOVSEPIAN DM, VESELY TM, PILGRAM TK, COYNE DW, SHENOY S. "Upper extremity central venous obstruction in hemodialysis patients: treatment with Wallstents.", *Radiology* 1997 Aug;204 (2):343-8. Department of Diagnostic Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, St Louis, MO 63110, USA.

*ANTHONY A. NICHOLSON, DUNCAN F. ETTLES, ANTHONY ARNOLD, MICHAEL GREENSTONE, JOHN F. DYET Treatment of Malignant Superior Vena Cava Obstruction: Metal Stents or Radiation Therapy *Journal of Vascular and Interventional Radiology* September 1997 (Vol. 8, Issue 5, Pages 781-788)

*VOGEL P, PARISE P. Smart stent for salvage of hemodialysis access grafts. *J Vasc Interv Radiol* 2004; 15:1051-1060.

*JONG-YOUN KIM, DONGHOON CHOI, YOUNG GUK KO, SUNGHA PARK, YANGSOO JANG AND DO YUN LEE. Percutaneous treatment of deep vein thrombosis in may-thurner syndrome. *CardioVascular and Interventional Radiology* Volume 29, Number 4 / August, 2006.

*JEFFREY P. LAMONT, MD, GREGORY J. PEARL, MD, PETER PATETSIOS, MD, MARC T. WARNER, MD, DENNIS R. GABLE, MD, WILSON GARRETT, MD, BRADLEY GRIMSLEY, MD, BERTRAM L. SMITH, MD, AND WILLIAM P. SHUTZE, MD, Prospective Evaluation of Endoluminal Venous Stents in the Treatment of the May-Thurner Syndrome. *Ann Vasc Surg* 2002; 16: 61-64

*NILESH H. PATEL, KENNETH R. STOOKEY, DOUGLAS B. KETCHAM, ANDREW H. Cragg Endovascular Management of Acute Extensive Iliofemoral Deep Venous Thrombosis Caused by May-Thurner Syndrome *Journal of Vascular and Interventional Radiology* November 2000 (Vol. 11, Issue 10, Pages 1297-1302)

Selected Literature References, Endovascular Repair of Abdominal Aortic Aneurysm (AAA)

ALLEN, BT, HOVSEPIAN, DM, REILLY, JM, et al. Endovascular Stent Grafts for Aneurysmal and Occlusive Vascular Disease. *Am J. Surg* 1998; 176:574-580.

BLUM, U, VOSHAGE, G, LAMMER, J, et. al. Endoluminal Stent-Graft for Infrarenal AAA. *NEJM* 1997;336: 13-20.

BREWSTER, DC, GELLER, SC, KAUFMAN, JA, et al. Initial Experience with Endovascular Aneurysm Repair: Comparison of Early Results with Outcome of Conventional Open Repair. *J Vasc Surg* 1998; 27: 992-1005.

CHUTER, TAM, Gordon, RL, REILLY, LM, et al. AAA in High Risk Patients: Short to Intermediate-term Results of Endovascular Repair. *Radiology* 1999;210:361-365.

D" AYALA, M., HOLLIER, LH, MARIN, ML. Endovascular Grafting for AAA. *Cardio. & Vasc. Surg* 1998;78:845-862.

DEATON, D.H., BOGEY, W.M., Bifurcated Endovascular Grafting for Abdominal Aortic Aneurysm., *Ann. Vasc. Surg.*, 1999; 13:23-31.

DORFFNER, R, THURNHER, S, POLTERAUER, P, et al. Treatment of AAA with Transfemoral Placement of Stent Grafts: Complications and Secondary Radiologic Intervention. *Radiology* 1997;204:79-86.

FINLAYSON, S.R.G., BIRKMEYER, J.D., Should Endovascular Surgery Lower the Threshold for Repair of Abdominal Aortic Aneurysms?, *J. Vasc. Surg.*, 1999; 29: 973-985.

HAUSEGGER, KA, MENDEL, H, TIESSENHAUSEN, K, et al. Endoluminal Treatment of Infrarenal Aortic Aneurysm: Clinical Experience with the Talent Stent-Graft System. *JVIR* 1999;10: 267-274.

KAZMERS, A., PERKINS, A.J., JACOBS, L.A., Outcomes after Aortic Aneurysm Repair in Those => 80 Years of Age: Recent Veterans Affairs Experience., *Ann. Vasc. Surg.*, 1998, 12:106-112.

MARIN, ML, PARSONS, RE, HOLLIER, LH, et al. Impact of Transrenal Aortic Endograft Placement on Endovascular Graft Repair of AAA. *J Vasc Surg* 1998;28:638-46.

MATSUMURA, J.S, MOORE, WS. Clinical Consequences of Periprostatic Leak After Endovascular Repair of AAA. *J Vasc Surg* 1998; 27:606-13.

MATSUMURA, JS, PEARSE, WH, McCARTHY, WJ, et al. Reduction in Aortic Aneurysm Size: Early Results After Endovascular Graft Placement. *J Vasc. Surg.*, 1997; 25:113-23.

MATSUMURA, J.S., CHAIKOF, E.L., Continued Expansion of Aortic Necks After Endovascular Repair of Abdominal Aortic Aneurysms, *J. Vasc. Surg.*, 1998, 28: 422-431.

MAY, J, WOODBURN, K, WHITE, G. Endovascular Treatment of Infrarenal AAA. *Ann Vasc Surg* 1998; 12:391-5.

MOORE, WS, RUTHERFORD, RB. Transfemoral Endovascular Repair of AAA: Results of the North American EVT Phase I Trial. *J Vasc. Surg* 1996; 23: 543-53.

MOORE, W.S., KASHYAP, V.S., et.al., AAA, A 6 Year Comparison Of Endovascular Versus Transabdominal Repair.; *Ann.of Surg.*, 1999: 230:298-308.

NASIM, A, THOMPSON, MM, SAYERS, RD, et al. Is Endoluminal Abdominal Aortic Aneurysm Repair Using an Aortoortic (Tube) Device a Durable Procedure? *Ann. Vasc. Surg* 1998; 12:522-528.

RESCH, T, IVANCEY, K, LINDH, M, et al. Persistent Collateral Perfusion of AAA After Endovascular Repair Does Not Lead to Progressive Change in Aneurysm Diameter. *J Vasc. Surg* 1998; 28:242-9.

SARKER, S., MOORE, W.S., et.al., Endovascular Repair of AAA Using the EVT Device: Limited Increased Utilization With Availability of a Bifurcated Graft. *J. Endovasc. Surg.*, 1999, 6:131-135.

SILBERSWEIG, JE, MARIN, ML, HOLLIER, LH, et al. Aortoiliac Aneurysms: Endoluminal Repair -Clinical Evidence for a Fully Supported Stent-Graft. *Radiology* 1998;209:111-116.

WAIN, RA, MARIN, ML, OHKI, T, et al. Endoleaks after Endovascular Graft Treatment of AAA: Classification, Risk Factors, and Outcome. *J Vasc Surg* 1998;27:69-80.

YUSEF, SW, WHITAKER, SC, CHUTER, TAM, et al. Early Results of AAA Surgery with Aortouniliac Graft Contralateral Iliac Occlusion, and Femerofemoral Bypass. *J Vasc Surg*;25:165-72.

ZARINS, CK, WHITE, RA, SCHWARTEN, D, et al. AneurRx Stent Graft Versus Open Surgical Repair of AAA: Multicenter Prospective Clinical Trial. *J. Vasc. Surg* 1999;29:292-305.

Prinssen M, Verhoeven EL, Buth J, Cuypers PW, van Sambeek MR, Balm R, et al; Dutch Randomized Endovascular Aneurysm Management (DREAM) Trial Group. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms. *N Engl J Med* 2004;351:1607-18.

*GREENHALGH RM, BROWN LC, KWONG GP, POWELL JT, THOMPSON SG. Comparison of endovascular aneurysm repair with open repair in patients with abdominal aortic aneurysm (EVAR trial 1), 30-day operative mortality results: randomised controlled trial. *Lancet* 2004; 364:843-8.

*SCHERMERHORN ML, O'MALLEY AJ, JHAVERI A, COTTERILL P, POMPOSELLI F, LANDON BE. Endovascular vs. open repair of abdominal aortic aneurysms in the medicare population., *N Engl J Med* 2008; 358:464-74.

*ELLIOT L. CHAIKOF, MD, PHD, A DAVID C. BREWSTER, MD, B RONALD L. DALMAN, MD, C MICHEL S. MAKAROUN, MD, D KARL A. ILLIG, MD, E GREGORIO A. SICARD, MD, F CARLOS H. TIMARAN, MD, G GILBERT R. UPCHURCH JR, MD, H AND FRANK J. VEITH, MD. The care of patients with an abdominal aortic aneurysm: The Society for Vascular Surgery practice guidelines. *iJOURNAL OF VASCULAR SURGERY* Volume 50, Number 8S

Selected Literature References, Endovascular Repair of Thoracic Aortic Aneurysm (TAA)
FDA approval for the GORE TAG Thoracic Endoprosthesis device: April 2005

LEURS LJ, BELL R, DEGRIECK Y, THOMAS S, HOBOR, LUNDBOM J; EUROSTAR; UK THORACIC ENDOGRAFT REGISTRY COLLABORATORS; Endovascular treatment of thoracic aortic diseases: combined experience from the EUROSTAR and United Kingdom Thoracic Endograft registries.; *J Vasc Surg.* 2004 Oct;40(4):670-9; discussion 679-80.

SCHODER, MARIA, ET AL; Elective Endovascular Stent-Graft Repair of Atherosclerotic Thoracic Aortic Aneurysms: Clinical Results and Midterm Follow-Up; *AJR* 2003; 180:709-715

LAWRENCE-BROWN, FRACS ET AL; Hybrid Open-Endoluminal Technique for Repair of Thoracoabdominal Aneurysm Involving the Celiac Axis; *Journal of Endovascular Therapy*: Vol. 7, No. 6, pp. 513-519.

*HODGSON KJ, MATSUMURA JS, ASCHER, E., DAKE MD, SACKS D, KROL K., BERSIN R.; SVS/SIR/SCAI/SVMB clinical competence statement on thoracic endovascular aortic repair (TEVAR)—multispecialty consensus recommendations, a report of the SVS/SIR/SCAI/SVMB Writing Committee to develop a clinical competence standard for TEVAR; *J Vasc Interv Radiol* 2006; 17:617-621

*HIMANSHU J. PATEL, MD, A DAVID M. WILLIAMS, MD, B GILBERT R. UPCHURCH JR, MD, NARASIMHAM L. DASIKA, MD, B AND G. MICHAEL DEEB, MD. A 15-year comparative analysis of open and endovascular repair for the ruptured descending thoracic aorta. *Journal of Vascular Surgery* DOI: 10.1016/j.jvs.2009.07.091

*BAVARIA JE, APPOO JJ, MAKAROUN MS, VERTER J, YU ZF, MITCHELL RS. Endovascular stent grafting versus open surgical repair of descending thoracic aortic aneurysms in low-risk patients: a multicenter comparative trial. *J Thorac Cardiovasc Surg.* 2007; 133: 369-377

Advisory Committee Meeting Notes

Meeting Date:

Wisconsin 02/12/2010

Illinois 01/13/2010

Michigan 01/14/2010

Minnesota 01/27/2010

J5 MAC 02/19/2010

Start Date of Comment Period

02/19/2010

End Date of Comment Period

Start Date of Notice Period

Revision History Number

Revision History Explanation

Reason for Change

Last Reviewed On Date

Related Documents

This LCD has no Related Documents.

LCD Attachments

Coding and Billing Guidelines.

Draft Contact

Kenneth Bussan - Kenneth.Bussan@wpsic.com
WPS Medicare
1717 W. Broadway
Madison, WI 53701-1787

All Versions



Updated on 12/23/2009 with effective dates N/A - N/A